Neuroblastoma cells (cyan) growing as a tumour and the surrounding collagen...
Neuroblastoma cells (cyan) growing as a tumour and the surrounding collagen matrix (magenta).

Image source: Garvan Institute of Medical Research

News • Randomness as resistance strategy

Cancer response to chemotherapy: a game of chance?

Inherent ‘noise’ in the system of gene expression in tumour cell death is another tool cancer cells use to resist chemotherapy treatment.

Cancer cells have an innate randomness in their ability to respond to chemotherapy, which is another tool in their arsenal of resisting treatment, new research led by the Garvan Institute of Medical Research shows. The new study is published in the journal Science Advances. Understanding why some tumour cells become resistant to chemotherapy is a core challenge in cancer research, as chemotherapy is still a frontline treatment for most cancers.

Combining chemotherapy with drugs that target this noise within tumours may have the best results as a first-line treatment after diagnosis, before tumours lock into a state of resistance

David Croucher

The new research shows that tumour cells from neuroblastoma – a cancer that develops in the body’s ‘fight or flight’ sympathetic nervous system – can move between states of responding, or not, to chemotherapy. “We showed there is ‘noise’ in the process of cell death, which is what happens to cancer cells after chemotherapy treatment – and that this inherent noise, or randomness, in the system of gene expression is an important aspect of chemoresistance,” says Associate Professor David Croucher, Head of the Network Biology Lab at Garvan. 

About 15% of people with neuroblastoma don’t respond to chemotherapy treatment. “Our findings suggest that genetics don’t account for everything; other layers of regulation and other mechanisms of tumour progression can also underpin drug response, so we need to consider them,” says Dr Sharissa Latham, co-lead author on the study. 

The team showed that once neuroblastoma cells reach a state of resisting chemotherapy, they can’t go back, suggesting there is a small window where treatment could work on a tumour cell before it’s locked in. “Combining chemotherapy with drugs that target this noise within tumours may have the best results as a first-line treatment after diagnosis, before tumours lock into a state of resistance,” says Associate Professor Croucher. This flips on its head the typical protocol for clinical trials in cancer where a new treatment is given to patients who have exhausted all other treatment options. 


Source: Garvan Institute of Medical Research

06.03.2023

Read all latest stories

Related articles

Photo

News • Protein controls resistance

Targeted approach holds promise to improve chemotherapy

Chemotherapy resistance is a main cause of treatment failure and death in cancer patients. Researchers from Brussels found how cancer cells protect themselves from the aggressive treatment.

Photo

News • MR-Linac measures oxygen levels

One step closer to targeted real time treatment of hypoxic cancers

Imaging researchers have taken a major step towards their ultimate goal of identifying cancers that are starved of oxygen so that altered treatment can be used to target them more effectively.

Photo

News • Making tumours susceptible to chemo

Breast cancer: target protein may hold key to therapy success

A rare variant of a protein present in nearly all human cells may hold the key to improving the effectiveness of breast cancer treatment, according to University of Manchester research.  

Related products

Alphenix 4D CT

Multi-Modality Suites

Canon · Alphenix 4D CT

Canon Medical Systems Europe B.V.
Aquilion Exceed LB

Oncology CT

Canon · Aquilion Exceed LB

Canon Medical Systems Europe B.V.
Aquilion LB

Oncology CT

Canon · Aquilion LB

Canon Medical Systems Europe B.V.
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Subscribe to Newsletter